CJC-1295 No DAC & Ipamorelin Buying Guide for Researchers

Buying CJC-1295 no DAC and ipamorelin for research comes down to four verifiable things: identity and purity confirmed by HPLC on the specific lot you receive, a batch document you can retrieve yourself rather than request, transparent wholesale pricing with stated minimums, and domestic fulfillment with intact lot traceability. Everything else — website design, a purity figure quoted with no lot attached, a "lab tested" badge — is marketing. Both compounds are research-use-only materials and are not approved drugs, not for human consumption, and not sold here for any clinical application.

This guide is written for the business buyer: the med spa owner, clinic operator, telehealth founder, or reseller deciding which supplier to build a catalog around. It covers how the two compounds differ on a spec sheet, what a purity number does and does not tell you, how wholesale tiers actually function, and which questions belong with your attorney rather than with a vendor.

Two signaling pathways, two different buying problems

CJC-1295 without DAC and ipamorelin appear together constantly in the research literature because they are structurally unrelated compounds that act on separate receptor systems. CJC-1295 no DAC — often referenced as modified GRF (1-29) — is a growth hormone-releasing hormone analog: a 29-amino-acid chain carrying substitutions that research indicates improve resistance to enzymatic degradation compared with native GHRH. The "no DAC" designation matters commercially. The DAC (Drug Affinity Complex) variant carries a linker that binds serum albumin, and studies indicate a substantially longer circulating presence; the non-DAC form does not, which changes how it is handled, stored, and studied.

Ipamorelin is a different animal entirely — a pentapeptide growth hormone secretagogue studied as a selective agonist at the ghrelin receptor. Research suggests its selectivity profile is what made it interesting to investigators relative to earlier secretagogues. Because the two act on distinct receptor pathways, preclinical literature frequently examines them in parallel rather than as substitutes.

From a purchasing standpoint, the practical consequence is that these are two separate quality problems. A 29-residue chain has more opportunities for deletion sequences, truncation, and incomplete coupling during synthesis than a five-residue chain does. Longer sequences generally carry more synthesis-related impurity risk, which means the batch documentation on a GHRH analog deserves closer reading than the documentation on a short peptide from the same supplier.

What a purity number actually tells you

Most suppliers publish a single percentage. It is worth understanding what that figure measures before you treat it as a decision input.

An HPLC purity result describes the proportion of peptide-related material in the sample that corresponds to the target sequence, as resolved by that chromatographic method. It is a relative measure across the peptide content — it is not a statement about what percentage of the vial's total mass is your compound. That second figure is net peptide content, and it is a different measurement. Lyophilized peptide powder also contains residual water and counterions left over from purification, commonly trifluoroacetate from reverse-phase methods. Two vials can both honestly report 99%+ HPLC purity and still differ in net peptide content.

This is not a reason to distrust purity figures. It is a reason to ask which figure a supplier is quoting, and whether the accompanying document shows the chromatogram or only a summary line. A chromatogram lets you see the shape of the result — whether impurities cluster near the main peak, which on a long sequence like a GHRH analog often points to synthesis byproducts.

Identity is the companion question. HPLC tells you how much of the sample is one thing; mass spectrometry tells you whether that thing has the expected molecular weight. A document reporting purity without any identity confirmation has told you a bottle contains something very pure. Real Peptides publishes 99%+ HPLC purity results on its catalog compounds, including CJC-1295 No DAC 10mg and Ipamorelin 10mg, with the underlying documentation available for buyers to check directly.

Reading batch documentation like a buyer, not a fan

The single most useful discipline in peptide procurement is refusing to accept a certificate of analysis that is not tied to the lot number printed on the vial you were shipped. A COA is a batch record. Detached from its batch, it is a sample of what the supplier's chemistry looked like at some unspecified moment.

When you evaluate any supplier — including this one — work through the document in this order:

Does the lot number on the document match the vial? If the supplier publishes one COA per compound rather than one per batch, you are looking at a specimen, not a record.

What was tested, and by whom? A purity assay alone is a narrow panel. Broader batch testing spans identity, purity, and contamination categories. Real Peptides runs 7-panel batch testing across its catalog; the useful question to put to any vendor is which categories their panel covers and whether the testing was performed in-house or by an independent laboratory. Both answers can be legitimate — an unwillingness to answer is the signal.

Can you retrieve the document without asking? Some suppliers gate COAs behind a support ticket, an account, or a fee. Publicly verifiable results mean you can confirm a lot before you commit to a purchase order, and so can a buyer doing diligence on you. Charging for the evidence that a product is what it claims to be is a practice worth walking away from.

Is the date and method stated? A document with no test date and no stated method is a design element.

If a supplier cannot answer these four questions in a single email, the pricing conversation is premature.

How wholesale pricing, tiers, and minimums work

Wholesale peptide pricing is structured around volume commitment and category. Suppliers set tiers because their own costs scale in steps — synthesis runs, purification batches, lyophilization cycles, and quality testing are largely fixed per batch, so cost per vial falls as batch size rises. That is the entire mechanism behind tiering, and it explains why minimums exist at all.

What this means for you as a buyer: margins, break points, and minimums vary widely by supplier, compound, and order size, and any vendor quoting you a universal figure before seeing your volume is guessing. Do not build a business plan on a number you found in a blog post — including this one, which is why no figures appear here.

What you should require is structural transparency. A wholesale program should state its minimums before you apply, price by tier rather than by negotiation theater, and make reorder pricing predictable so your own costing does not move every quarter. Hidden pricing — "contact us for a quote" as the only available information — is not inherently disqualifying, but it shifts all the information asymmetry to the seller.

Ask about fulfillment mechanics with the same rigor. Where does the order ship from? Domestic fulfillment shortens the chain between batch release and your shelf and reduces customs variables. Real Peptides fulfills from the US in 5–7 days. Ask how lot segregation works on multi-item orders, whether cold-chain handling applies to any catalog item, and what the process is if a shipment arrives compromised. These are operational answers, and a supplier who runs a real fulfillment operation will have them ready.

The questions that belong with your attorney

This section is informational and is not legal advice. Nothing here is medical or veterinary advice either — any question touching use in a living subject belongs with a licensed physician or veterinarian, not with a supplier or a buying guide.

Research compounds sit in a regulatory area where the answers depend on your business model, your jurisdiction, and facts about your operation that no article can know. Rather than tell you what the rules are, here is what to put in front of counsel and your state board before you stock anything:

• How does your state characterize the resale of research-use-only materials, and does your business structure change that analysis?
• What licensing, registration, or professional oversight requirements may apply to your entity specifically?
• What labeling, record-keeping, and lot-traceability obligations attach to materials you resell?
• How should your marketing be constrained so that research-use-only framing is maintained end to end?
• What does your professional liability coverage actually cover for this product category?

Treat any supplier who answers these questions for you with suspicion. A vendor telling you that resale is permitted in your state is offering a legal conclusion they are not positioned to give. The correct supplier answer is documentation and a referral to your own counsel.

What Real Peptides does differently

Real Peptides publishes 99%+ HPLC purity results and runs 7-panel batch testing on catalog compounds. The certificates of analysis are publicly verifiable — you can pull the lab results yourself, before you order, without opening a support ticket or paying for access. That is a deliberate inversion of the common industry pattern where testing evidence is gated, summarized, or unattached to a specific batch.

Fulfillment runs domestically in 5–7 days, with lot traceability maintained from batch release through delivery. Wholesale access runs through a 3-step application: apply, get reviewed for fit and volume, and receive tier pricing. The review step exists because wholesale is a business relationship, not a coupon code.

Everything in the catalog is sold for laboratory research use only. Real Peptides does not supply semaglutide, tirzepatide, retatrutide, or melanotan, and does not pair compounds with supplies in a way that implies anything beyond research handling.

Where qualified buyers go from here

If you are sourcing GHRH analogs and secretagogues at volume and your diligence checklist starts with batch-level documentation rather than price, the Wholesale Partner Program application is the next step. Bring your expected volume, your compound list, and your compliance questions — the first two get you tier pricing, and the third gets you the documentation your counsel will want to see.

Beyond the two compounds covered here, the catalog extends to related research materials including Tesamorelin 10mg and BPC-157 10mg, and buyers building a broader catalog can review the full performance and recovery research collection or the popular peptides range to see how batch documentation is presented across compound categories.